Search

Advanced wells play a crucial role in maximizing the efficiency of oil production. To achieve a successful design for advanced wells, several parameters must be considered and evaluated. Uncertainty in these parameters can have a significant impact on the performance assessment of the well in its lifetime. Absolute permeability, relative permeability, and permeability anisotropy are the parameters that determine reservoir permeability and are among the most important design parameters to be considered. This paper aims to assess the performance of advanced wells completed with passive and reactive downhole Flow Control Devices (FCDs) under uncertainty in the reservoir permeability parameters. The assessment is conducted through a case study on a synthetic heavy oil reservoir with a strong water drive. The EclipseSM reservoir simulator is used as a simulation tool and the Latin Hypercube Sampling (LHS) approach is applied as a sampling tool for uncertainty analysis in this study. According to the obtained results, under the presence of uncertainty, advanced wells with Autonomous Inflow Control Device (AICD) and Autonomous Inflow Control Valve (AICV) completions are able to mitigate the risk of water production by 53.20% and 71.12% respectively compared to conventional wells. However, Inflow Control Device (ICD) completion can only reduce the risk by 0.87%.

Background: Leukocyte phytohemagglutinin (PHA-L), derived from the L4 tetramer of PHA, has been frequently employed as a mitogen to induce T lymphocyte proliferation in vitro. The biological application of PHA-L in cancer diagnosis and treatment has gained traction in recent years. However, it has been noted that PHA-L obtained using traditional procedures has a massive amount of impurities or toxic components, which interfere with the activity of PHA-L. Preparation of a monoclonal antibody against active PHA-L is a significant tool for studying PHA-L's function and therapeutic potential. Results: We successfully prepared monoclonal antibodies against the active components of PHA-L based on the whole PHA-L protein as an antigen, and found that monoclonal antibody 3C1C6G11 can be employed in western blot, immunofluorescence, and immunohistochemistry detection. Importantly, preliminary result shows that the mAb 3C1C6G11 may prevent PHA-L-induced cell aggregation and AICD (activation-induced cell death). Conclusions: The monoclonal antibody mAb 3C1C6G11 prepared in this study can be used as an effective tool for detecting PHA-L active components, investigating PHA-L's function and antineoplastic application. [ABSTRACT FROM AUTHOR]